AU2016277708B2 — Apoptosis-inducing agents for the treatment of cancer and immune and autoimmune diseases
Assigned to Walter and Eliza Hall Institute of Medical Research · Expires 2018-11-08 · 8y expired
What this patent protects
Apoptosis-inducing agents for the treatment of cancer and immune and autoimmune diseases Disclosed are compounds which inhibit the activity of anti-apoptotic Bcl-2 proteins, compositions containing the compounds and methods of treating diseases during which is expressed anti-apop…
USPTO Abstract
Apoptosis-inducing agents for the treatment of cancer and immune and autoimmune diseases Disclosed are compounds which inhibit the activity of anti-apoptotic Bcl-2 proteins, compositions containing the compounds and methods of treating diseases during which is expressed anti-apoptotic Bcl-2 protein.
Drugs covered by this patent
- Venclexta (venetoclax) · AbbVie
Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.
Track this patent
Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.